

A. Federal Reserve Bank of Cleveland
(Douglas A. Banks, Vice President) 1455
East Sixth Street, Cleveland, Ohio
44101-2566:

1. *KeyCorp, and KYCA Corporation*,
both of Cleveland, Ohio; to merge with
U.S.B. Holding Co. Inc., Orangeburg,
New York, and thereby indirectly
acquire Union State Bank, Nanuet, New
York.

In connection with this application,
KYCA Corporation; has applied to
become a bank holding company by
acquiring 100 percent of the voting
shares of Union State Bank, Nanuet,
New York.

Board of Governors of the Federal Reserve
System, September 7, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-17944 Filed 9-11-07; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of
Governors of the Federal Reserve
System.

TIME AND DATE: 12:00 p.m., Monday,
September 17, 2007.

PLACE: Marriner S. Eccles Federal
Reserve Board Building, 20th and C
Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments,
promotions, assignments,
reassignments, and salary actions)
involving individual Federal Reserve
System employees.

2. Any items carried forward from a
previously announced meeting.

FOR FURTHER INFORMATION CONTACT:

Michelle Smith, Director, or Dave
Skidmore, Assistant to the Board, Office
of Board Members at 202-452-2955.

SUPPLEMENTARY INFORMATION: You may
call 202-452-3206 beginning at
approximately 5 p.m. two business days
before the meeting for a recorded
announcement of bank and bank
holding company applications
scheduled for the meeting; or you may
contact the Board's Web site at <http://www.federalreserve.gov> for an electronic
announcement that not only lists
applications, but also indicates
procedural and other information about
the meeting.

Board of Governors of the Federal Reserve
System, September 7, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 07-4492 Filed 9-7-07; 5:02 pm]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Draft Performance Standards for the Murine Local Lymph Node Assay: Request for Comments

AGENCY: National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH).

ACTION: Request for comments.

SUMMARY: The Murine Local Lymph
Node Assay (LLNA) is the first
alternative test method evaluated and
recommended by the Interagency
Coordinating Committee on the
Validation of Alternative Methods
(ICCVAM). It was subsequently
accepted by regulatory authorities to
determine the allergic contact dermatitis
potential of chemicals and products. In
January 2007, the U.S. Consumer
Product Safety Commission (CSPC)
submitted a nomination requesting that
NICEATM and ICCVAM assess the
validation status of (1) The LLNA as a
stand-alone assay for potency
determination for hazard classification
purposes; (2) modified LLNA protocols;
(3) the LLNA limit test; (4) the use of
LLNA to test mixtures, aqueous
solutions, and metals; and (5) the
applicability domain for LLNA. In order
to facilitate the review of the modified
LLNA protocols, ICCVAM proposed
developing performance standards for
the LLNA. In May 2007, a **Federal
Register** notice was published (Vol. 72,
No. 95, pages 27815-27817, May 17,
2007) requesting comments and data
relevant to these nominated activities.
In June 2007, the Scientific Advisory
Committee on Alternative Toxicological
Methods (SACATM) endorsed the
nominated activities as high priorities
for ICCVAM. In response to SACATM
comments, along with those provided
by the public in response to the
previous **Federal Register** notice,
ICCVAM also endorsed these activities
as high priorities. ICCVAM
subsequently prepared draft
performance standards for the LLNA
and now requests public comments on
this draft document, which is available
on the NICEATM/ICCVAM Web site at:
(<http://iccvam.niehs.nih.gov/methods/immunotox/immunotox.htm>) or by
contacting NICEATM (see **FOR FURTHER
INFORMATION CONTACT** below).

DATES: Submit comments on or before
October 29, 2007.

ADDRESSES: Dr. William S. Stokes,
NICEATM Director, NIEHS, P.O. Box

12233, MD EC-17, Research Triangle
Park, NC 27709, (fax) 919-541-0947, (e-
mail)

niceatm@niehs.nih.gov. Courier address:
NICEATM, 79 T.W. Alexander Drive,
Building 4401, Room 3128, Research
Triangle Park, NC 27709. Responses can
be submitted electronically at the
ICCVAM-NICEATM Web site: http://iccvam.niehs.nih.gov/contact/FR_pubcomment.htm or by e-mail, mail,
or fax.

FOR FURTHER INFORMATION CONTACT:

Other correspondence should be
directed to Dr. William S. Stokes (919-
541-2384 or niceatm@niehs.nih.gov).

SUPPLEMENTARY INFORMATION:

Background

The LLNA is an alternative test
method used for skin sensitization
testing that reduces the number of
animals needed, reduces the time
required for testing, and can
substantially reduce or avoid pain and
distress associated with traditional
guinea pig testing methods. The LLNA
was the first alternative test method
evaluated and recommended by
ICCVAM and based on the
recommendations of ICCVAM and an
independent scientific peer review
panel, the LLNA has been accepted by
U.S. and international regulatory
authorities as an alternative to the
guinea pig maximization test and
Buehler test for assessing allergic
contact dermatitis (EPA 2003; ISO 2002;
OECD 2002). Since 2003, ICCVAM has
routinely developed performance
standards for test methods; however,
because the concept of performance
standards was not developed by
ICCVAM until 2003, they were not
developed during the ICCVAM
evaluation of the LLNA in 1998 (NIH
Publication No. 99-4494, available:
(http://iccvam.niehs.nih.gov/docs/immunotox_docs/llna/llnarep.pdf).

In January 2007, CSPC submitted a
nomination requesting that NICEATM
and ICCVAM assess the validation
status of (1) The LLNA as a stand-alone
assay for potency determination for
classification purposes; (2) modified
LLNA protocols; (3) the LLNA limit test;
(4) the use of LLNA to test mixtures,
aqueous solutions, and metals; and (5)
the applicability domain for LLNA.
ICCVAM endorsed the nomination and
also decided to develop performance
standards to facilitate evaluation of
modified LLNA protocols to the
traditional LLNA. In May 2007, a
Federal Register notice was published
requesting comments and data relevant
to these activities (Vol. 72, No. 95, pages
27815-27817, May 17, 2007; available,